PMID- 8810934
OWN - NLM
STAT- MEDLINE
DCOM- 19961022
LR  - 20190905
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 240
IP  - 2
DP  - 1996 Aug
TI  - A multicentre comparison of once-daily subcutaneous dalteparin (low molecular 
      weight heparin) and continuous intravenous heparin in the treatment of deep vein 
      thrombosis.
PG  - 85-92
AB  - OBJECTIVES: To compare the efficacy and safety of the low molecular weight 
      heparin (LMWH) dalteparin with unfractionated heparin (UFH) in the acute 
      treatment of DVT patients who had not previously received UFH. DESIGN: An open 
      randomized multicentre trial with blinded analysis of venograms. SETTING: Seven 
      hospitals in Sweden, Finland and the USA. SUBJECTS: A total of 330 patients, of 
      20 years or older, with suspected DVT, verified using venography. INTERVENTIONS: 
      Fixed-dose dalteparin (200 IU kg-1) given as a once-daily subcutaneous injection, 
      or aPTT adjusted i.v. UFH infusion for 6 to 10 days. MAIN OUTCOME MEASURES: 
      Change in Marder score in patients with confirmed DVT and two evaluable 
      venograms; PE, bleeding events and follow-up. RESULTS: Marder scores improved in 
      51% (95% CI 42-60%) of 92 patients treated with dalteparin and in 62% (95% CI 
      53-70%) of 98 patients treated with UFH (P = 0.152). One dalteparin-treated 
      patient had a PE confirmed by V/Q scan; another had progressive thrombosis with 
      swelling in the affected limb. Bleeding complications occurred in six patients in 
      each group. One patient treated with dalteparin and five treated with UFH died 
      during the 6-month follow-up period as a result of underlying malignancy or heart 
      disease. The 6-month recurrence rate was low with both treatments (dalteparin, 
      3/97; UFH, 2/103). CONCLUSIONS: Fixed-dose subcutaneous dalteparin given once 
      daily from the start of treatment is of equivalent efficacy and safety to 
      conventional UFH therapy in the routine management of DVT.
FAU - Luomanmaki, K
AU  - Luomanmaki K
AD  - University of Helsinki, Finland.
FAU - Grankvist, S
AU  - Grankvist S
FAU - Hallert, C
AU  - Hallert C
FAU - Jauro, I
AU  - Jauro I
FAU - Ketola, K
AU  - Ketola K
FAU - Kim, H C
AU  - Kim HC
FAU - Kiviniemi, H
AU  - Kiviniemi H
FAU - Koskivirta, H
AU  - Koskivirta H
FAU - Sorskog, L
AU  - Sorskog L
FAU - Vilkko, P
AU  - Vilkko P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hemoglobins)
RN  - 9005-49-6 (Heparin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Dalteparin/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Follow-Up Studies
MH  - Hematocrit
MH  - Hemoglobins
MH  - Heparin/*administration & dosage/adverse effects
MH  - Humans
MH  - Infusions, Intravenous
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Risk Factors
MH  - Thromboembolism/etiology/prevention & control
MH  - Thrombosis/blood/complications/*drug therapy
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.1046/j.1365-2796.1996.18845000.x [doi]
PST - ppublish
SO  - J Intern Med. 1996 Aug;240(2):85-92. doi: 10.1046/j.1365-2796.1996.18845000.x.